Contact Us
  • Choose License Type

Global Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type  (Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), and Other Non-malignant Disorders), by Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), and Cord Blood Transplant (CBT))and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,092.6 million in 2020 and is expected to exhibit a CAGR of 11.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key players in the market are involved in strategic collaborations with biopharmaceutical companies and research institutes for development of stem cell therapies. Such strategic collaborations are expected to create conducive environment for growth of the global hematopoietic stem cell transplantation market in the near future.

For instance, Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell, in December 2017, collaborated with Anthony Nolan, a blood cancer research organization, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product.

In January 2019, Gamida Cell Ltd., a leading cellular and immune therapeutics company, and Lonza entered a strategic manufacturing agreement for commercial production after the U.S. FDA approval of omidubicel, currently in clinical development, designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Impact of Coronavirus (Covid-19) Pandemic

According to the article published in National Center for Biotechnology Information (NCBI), May 4, 2020, American Society for Transplantation and Cellular Therapy (ASTCT) and the European Society for Blood and Marrow Transplantation (EMBT) has issued guidelines for the recipients and donors of HSCT.

According to the article published in National Center for Biotechnology Information (NCBI) on May 4, 2020, if the recipient contracts or comes in contact with the coronavirus infected person, then the stem cell transplant procedure should be postponed, till the person is tested negative after two repeated RT-PCR tests. Moreover, before the procedure, the recipient is advised to quarantine themselves for 14 days, which reduces the chances of coming in contact with the infected person. Furthermore, if the stem cell donor gets infected with COVID-19, then the donor is excluded from the stem cell donation lists. If the donor comes in contact with COVID-19 patients or they travel to high-risk areas, then they are excluded from donation for at least 28 days.

According to the World Health Organization, both the donor and recipients should avoid crowded places and large group gatherings at least 28 days before the transplant procedure.

According to the guidelines issued by European Society for Blood and Marrow Transplantation (EMBT) for post HSCT and post CAR-T cell recipients: March 23, 2020, the individuals coming in contact with the recipient and donors are expected to maintain social distancing, travel by private car, wash hands, and others. If the recipient is tested positive for COVID-19, then the patient should be evaluated and treated for the same, by following all the guidelines.

Browse 35 Market Data Tables and 33 Figures spread through 208 Pages and in-depth TOC on Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type  (Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) and Other Non-malignant Disorders), by Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT) and Cord Blood Transplant (CBT))and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027"

To know the latest trends and insights related to Hematopoietic Stem Cell Transplantation (HSCT) Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hematopoietic-stem-cell-transplantation-market-1250

Key Takeaways of the Hematopoietic Stem Cell Transplantation (HSCT) Market:

  • The global hematopoietic stem cell transplantation market is expected to exhibit a CAGR of 11.2% during the forecast period (2020-2027) owing to increasing strategic collaborations among key players.
  • Among transplant type, the allogeneic segment is expected to hold a major revenue share in 2027 owing to rising number of allogeneic hematopoietic stem cell transplantation. For instance, according to the European Society for Blood and Marrow Transplantation (EBMT) Survey 2018, the transplant count in 50 reporting countries including Algeria, South Africa, Tunisia and are as follows:
  • Major players operating in the global hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner